Viatris Inc (VTRS) Stock
VTRS has an Alpha Score of 62 out of 100 (moderate), computed on Nov 1, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 19 trades in VTRS since 2020: 6 purchases and 11 sales, most recently Gilbert Cisneros (purchase, Nov 18, 2025). 8 of the hedge funds AlphaScala tracks reported VTRS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Greenlight Capital's at $44.04M.
What is VTRS's Alpha Score?
How it works →Alpha Score of 62 reflects moderate overall profile with strong momentum, strong value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 1, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Viatris Inc (VTRS)?
Most recent: Gilbert Cisneros (purchase, Nov 18, 2025); records start Nov 17, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2025-11-18 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-03-31 | partial sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-02-25 | purchase | $1k – $15k |
| Dan Goldman D-NY · House | 2023-04-10 | partial sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-03-06 | partial sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-01-31 | purchase | $1k – $15k |
| Earl Blumenauer D-OR · House | 2022-03-14 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all VTRS political trades →Which hedge funds own VTRS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Greenlight Capital David Einhorn | 2.77M | $44.04M | +53% |
| Bridgewater Associates Ray Dalio | 1.70M | $26.97M | +134% |
| Marshall Wace | 840K | $13.34M | -91% |
| D.E. Shaw David Shaw | 791K | $12.57M | -80% |
| Point72 Steve Cohen | 563K | $8.94M | -68% |
| Citadel Ken Griffin | 502K | $7.98M | -87% |
| Millennium Management Israel Englander | 314K | $4.99M | -89% |
| Blackstone | 53K | $834.0K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are VTRS's key statistics?
Key statistics as of Nov 2, 2026
How does VTRS's valuation compare with the Healthcare sector?
| Metric | VTRS | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -2.79% | 4.31% | 164 |
| Return on equity | -2.79% | 5.47% | 185 |
| Dividend yield (payers) | 5.09% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
VTRS price chart
Powered by TradingViewWhat does Viatris Inc do?
Viatris Inc. is a global healthcare company that develops, manufactures, and markets a broad portfolio of branded and generic pharmaceutical products. It specializes in generics, including commoditized and complex varieties as well as biosimilars, alongside legacy branded medicines such as Lipitor, Norvasc, Lyrica, and Viagra. The company addresses multiple therapeutic areas, including cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare, with particular focus on dermatology, ophthalmology, and gastroenterology. Viatris Inc. serves patients in over 165 countries through its extensive product offerings in the specialty and generic drug sectors. Founded in 2019 and headquartered in Canonsburg, Pennsylvania, it operates as one of the largest generic drug manufacturers worldwide, providing essential medicines and treatments to diverse healthcare markets.